Pet Owners Cut Vet Visits as Spending Slips

Dog and cat owners are trimming veterinary care, and the cost pressure is reaching the medicine makers who serve them.

Updated on Nov. 5, 2026 in Pet Health

Pet Owners Cut Vet Visits as Spending Slips

Live Poll

Do you expect your pet care costs to rise over the next year?

Animal health company Zoetis reported third-quarter 2026 adjusted earnings of $1.75 per share, beating analyst expectations of $1.51, while its U.S. companion animal business declined and the company raised its full-year guidance. Shares fell 6.10% to $83.76 on the report day, Thursday, November 5, 2026.

Why it matters

Pet owners facing higher costs are trimming veterinary care, which shows up as fewer clinic visits and lower spending on pet medicines that households depend on. Zoetis linked the decline to macro-driven price sensitivity and high housing costs that are reducing pet adoption, meaning fewer dogs are joining American households.

Third-quarter canine vet visits fell around 5%, and U.S. segment revenue came in at $1.2 billion, down 6% on a reported and organic operational basis. Zoetis raised its fiscal 2026 adjusted EPS guidance from $6.15-$6.25 to $6.25-$6.35.

The players

Zoetis

A major animal health company whose product lines include the companion animal medicines Convenia and Cerenia, now facing generic competition.

The details

Zoetis attributed the companion animal slump to three forces: price-sensitive pet owners, competitive pressure in dermatology, and generic versions of its products Convenia and Cerenia that are drawing volume away from the brand. Volume losses to these generics are the main reason the U.S. companion business shrank even as overall earnings beat expectations. The company said it will plan 2027 prudently without assuming any recovery in pet owner spending, and expects limited contribution from new launches next year, with impact building later and into 2028.

Year-to-date 2026: U.S. clinic visits down 3% across categories.
Third quarter 2026: Quarterly earnings reported and canine vet visits fell around 5%.
Thursday, November 5, 2026: Zoetis shares fell 6.10% to $83.76.
2027: Limited contribution expected from new commercial launches.
2028: Expected impact of new commercial strategies begins to build.

The Home Front

Zoetis's U.S. companion animal revenue fell 8% in the quarter while its livestock business rose 5%, a split that signals household pet spending is the softer part of the market. The decline sits alongside high housing costs that are reducing how many dogs join American homes.

If you are budgeting for a dog or cat, expect veterinary visits and prescription costs to keep pressing on household budgets, so build a savings buffer before a routine visit becomes urgent. Ask your veterinarian whether a generic version of a prescribed medication is appropriate, and keep your pet's records organized so any change in treatment is easy to track.

The takeaway

Pet care costs are being felt through fewer clinic visits and tighter household spending, not just at the checkout counter. Keep a current copy of your pet's medication list and ask your veterinarian about lower-cost generic options before you need them.